In Vivo

Show me the money

Show me the money

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

By Anil Shrivastava, David Bellaire and Ashish Singh

  • min read

Article

Show me the money
en

Drug companies pay MCO's too much in rebates and get too little in return—but "fair share" analysis can help, for some drugs, drive as much as $100 million in additional revenues.

Download the Full Report (pdf)
Tags

How We've Helped Clients

A Medical Imaging Company’s CX Overhaul Boosts Customer Satisfaction and Revenue

Read case study

Strategy A healthcare payer sets its own long-term health strategy

Read case study

People and Organization A Regional Operating Model Lifts European Sales for a Medical Device Maker

Read case study

Ready to talk?

We work with ambitious leaders who want to define the future, not hide from it. Together, we achieve extraordinary outcomes.

Contact Bain

How can we help you?

See all offices